VEGFR2/CD309 Antikörper (AA 20-678)

Produktnummer ABIN616030

Dieses Anti-VEGFR2/CD309-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von VEGFR2/CD309 in WB. Geeignet für Human.

Kurzübersicht für VEGFR2/CD309 Antikörper (AA 20-678) (ABIN616030)

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VEGFR2/CD309 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-VEGFR2/CD309 Antikörper

Bindungsspezifität: AA 20-678

Spezifität: This antibody detects CD309 / VEGFR-2 / Flk-1.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Protein-A purified

Immunogen: Highly pure (>95%) recombinant human esKDR (Ala20-Pro678) derived from insect cells

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS, pH 7.2

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable at room temperature for up to 1 month. Following reconstitution antibody can be stored at 2-8 °C for up to two weeks or (in aliquots) at -20 °C for longer.

Details zu VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: CD309 / VEGFR-2 / Flk-1

Hintergrund: Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels, modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema. Recombinant human esKDR generated by alternative splicing consist of the first 6 Ig-like loops followed by the unique C-terminal end: CGRETILDHSAEAVGMP.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2

Gen-ID: 3791

NCBI Accession: NP_002244

UniProt: P35968

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling